Description
HF50 is an experimental drug being studied in patients with advanced solid tumors, including some types of colorectal cancer. It is being tested in Phase 1 clinical trials to determine its safety and how it should be dosed. HF50 is designed to work in two main ways: first, it uses liposomes (tiny fat bubbles) to bring immune cells (T-cells) closer to cancer cells that have certain markers (like HER2). Second, it contains a substance that activates the immune system within the tumor, aiming to create a stronger attack against the cancer. This drug is given as an intravenous (IV) infusion. The trials are looking at how well it is tolerated, how it affects the body (pharmacokinetics), how the immune system responds, and if it shows any early signs of shrinking tumors.
Mechanism of Action
HF50 is a liposome-encapsulated T-cell engager. It aims to redirect T-cells (a type of immune cell) to target cancer cells. The liposomes carry molecules that bind to both a tumor-associated antigen (like HER2, which is found on some cancer cells) and CD3 (a marker on T-cells). This brings the T-cells close to the cancer cells. Additionally, HF50 contains a TLR7/8 agonist, which is designed to activate the innate immune system within the tumor environment, potentially enhancing the overall immune response against the cancer.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.